<法規>
<法規性質>法律</法規性質>
<英文法規名稱>The Plasma Derivatives Act</英文法規名稱>
<中文法規名稱>血液製劑條例</中文法規名稱>
<法規網址>http://law.moj.gov.tw/Eng/LawClass/LawContent.aspx?PCODE=L0020118</法規網址>
<最新英文異動日期>20050119</最新英文異動日期>
<廢止註記>
</廢止註記>
<附件 />
<沿革內容><![CDATA[1.Promulgated on January 19th, 2005. The Regulations shall be effective one year after.
  Text of Article 2, the competent authority was amended from the Department of Health, Executive Yuan to the Ministry of Health and Welfare and effective since July 23th, 2013, per Executive Yuan announcement Yuan-Tai-Guay No.1020141353 on July 19th, 2013.]]></沿革內容>
<前言><![CDATA[]]></前言>
<法規內容>
  <條文>
    <條號>Article 1</條號>
    <條文內容><![CDATA[This Act is legislated to enhance the safety and quality of plasma derivatives and assure a stable supply thereof in order to protect the public health. Matters not provided for under this Act shall be governed by the provisions of the Medical Care Act, the Pharmaceutical Affairs Act, and other relevant acts.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 2</條號>
    <條文內容><![CDATA[he term “competent authority” refers to theMinistry of Health and Welfare at the central government level, municipal governments at the municipal level, and county (city) governments at the county (city) level.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 3</條號>
    <條文內容><![CDATA[The term “plasma derivative” refers to a pharmaceutical product of a certain form of dosage prepared and processed from human plasma.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 4</條號>
    <條文內容><![CDATA[The materials for plasma derivatives shall be obtained from domestic blood donations. However, in the event that the domestic supply of such materials should become insufficient, plasma derivative manufacturers may, subject to the approval of the central competent authority, import the materials from foreign countries.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 5</條號>
    <條文內容><![CDATA[To meet the domestic demand and supply of plasma derivatives, the competent authority shall actively adopt educational and promotional measures to encourage local blood donation.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 6</條號>
    <條文內容><![CDATA[To ensure the safety, quality, and stable supply of plasma derivatives, as well as to promote research and local industrial development, the central competent authority shall promulgate development programs for plasma derivatives.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 7</條號>
    <條文內容><![CDATA[Blood donation institutions shall make efforts to promote blood donation, enhance the safety of the materials used for plasma derivatives, assist in ensuring a stable supply, and adopt measures to protect the health of blood donors.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 8</條號>
    <條文內容><![CDATA[Plasma derivative manufacturers shall meet the standards of Good Manufacturing Practices (GMP) and provide safe and good quality plasma derivatives.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 9</條號>
    <條文內容><![CDATA[Medical institutions and physicians shall give preference to plasma derivatives made from blood donated domestically and provide patients with prescription information on such usage.
To respect patients’ wishes in choosing the preparations to be used, the use of preparations manufactured by other materials, methods or genetic engineering is not restricted by the preceding paragraph.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 10</條號>
    <條文內容><![CDATA[Blood donation institutions shall establish annual blood collection plans, which shall include the blood volume from donations and for therapeutic needs, the plasma volume for plasma derivatives manufacturing, and the blood drive activities. The aforementioned plans shall be submitted to the central competent authority for further reference.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 11</條號>
    <條文內容><![CDATA[Plasma derivative manufacturers and importers shall periodically report their estimated and actual manufactured or imported quantity of plasma derivatives to the central competent authority for further reference.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 12</條號>
    <條文內容><![CDATA[The central competent authority shall establish and announce annual plans regarding the estimated demand for plasma derivatives.
The aforementioned plan shall include the following items:
1. Categories of plasma derivatives
2. Categories and the targeted volume of plasma derivatives to be manufactured and imported annually
3. Volume of blood materials needed for said targeted volume of plasma derivatives
4. Quantity of interchangeable pharmaceutical products in lieu of plasma derivatives
5. Other matters related to the effective utilization of blood materials
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 13</條號>
    <條文內容><![CDATA[Blood donation institutions may engage in the manufacturing of plasma derivatives with the blood materials collected, or with the approval of the central competent authority, supply such blood materials to other plasma derivative manufacturers.
Blood donation institutions may charge at cost for the aforementioned supply to the plasma derivative manufacturers. The amount of said charge shall be submitted to and approved by the central competent authority.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 14</條號>
    <條文內容><![CDATA[Blood donation institutions shall implement health screening on blood donors before collecting their blood.
The standards for health requirements of blood donors and the items of the aforementioned health screening shall be respectively prescribed by the central competent authority.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 15</條號>
    <條文內容><![CDATA[When necessary, blood donation institutions shall provide plasma derivative manufacturers with essential informations, including collection date, examination items and results, and donors’ information, so as to prevent the health hazards caused by blood materials.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 16</條號>
    <條文內容><![CDATA[Violation of Articles 10 and 11 shall be subject to an administrative fine of no less than twenty thousand and no more than one hundred thousand New Taiwan Dollars, imposed by the central competent authority together with an order to take corrective action within a prescribed time. Failure to resolve the issue by the prescribed time may be subject to further fines successively for each violation.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 17</條號>
    <條文內容><![CDATA[Failure to comply with the administrative fines imposed under these Acts by the prescribed time shall result in compulsory enforcement [or injunctive relief] pursuant to the relevant laws.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 18</條號>
    <條文內容><![CDATA[The enforcement rules [of this Act] shall be promulgated by the central competent authority.
]]></條文內容>
  </條文>
  <條文>
    <條號>Article 19</條號>
    <條文內容><![CDATA[This Act shall take effect one year after the presidential announcement.
]]></條文內容>
  </條文>
</法規內容>
</法規>
